Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000 ® (Smallpox and Mpox (Vaccinia) Vaccine, Live) ...

The vaccine is administered percutaneously using a bifurcated needle that is dipped into the vaccine solution; the skin is then pricked several times in the upper arm. The Food and Drug Administration ...

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics ...

On Wednesday, Emergent BioSolutions Inc. (NYSE:EBS) said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio. What ...

As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially joined the ranks of FDA-approved defense measures against the virus. The FDA ...

Emergent BioSolutions Inc. EBS announced that the FDA has approved its supplemental biologics license application (sBLA) seeking a label expansion for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, ...

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ...

On the heels of the World Health Organization's (WHO) global emergency declaration, the FDA expanded the approval of the smallpox vaccine (ACAM2000) for use in people at high risk for mpox, developer ...

GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its ...

Bavarian Nordic is planning to dramatically scale up production capacity for its Jynneos vaccine in the event of a smallpox emergency, CEO Paul Chaplin said. Chaplin said the sudden and rapid spread ...